ARROWHEAD PHARMACEUTICALS, INC. Selling, General and Administrative Expense
ARROWHEAD PHARMACEUTICALS, INC. (ARWR) reported Selling, General and Administrative Expense of $47.12 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-04
- ARROWHEAD PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-06-30 was $47.12M, a 52.26% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2026-03-31 was $41.74M, a 46.96% increase year-over-year.
- ARROWHEAD PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-06-30 was $30.95M.
- ARROWHEAD PHARMACEUTICALS, INC. selling, general and administrative expense for the quarter ending 2025-03-31 was $28.41M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month |
|---|---|---|---|
| 2026-06-30 | $47.12M 10-Q · filed 2026-08-04 | $88.87M derived: sum of 2 quarters · filed 2026-08-04 | $134.89M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $41.74M 10-Q · filed 2026-05-07 | $87.77M 10-Q · filed 2026-05-07 | |
| 2025-06-30 | $30.95M 10-Q · filed 2026-08-04 | $59.35M derived: sum of 2 quarters · filed 2026-08-04 | $86.26M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $28.41M 10-Q · filed 2026-05-07 | $55.31M 10-Q · filed 2026-05-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 |